Lice treatment launch
This article was originally published in The Rose Sheet
Executive Summary
Australian firm Wild Child hopes to gain a 20% share of the $100 mil. over-the-counter head lice treatment market in the U.S. within a 12-month period following the introduction of its Quit Nits natural lice treatment product in the region, company announces Jan. 23. Under a recent distribution agreement with CVS, Quit Nits will be available in 44 states across the U.S., the firm notes. Comprising a treatment cream and a "first-of-its kind" preventative spray, Quit Nits offers consumers a homeopathic and natural approach to removing lice, company claims. The formulas contain natural actives that have been found in an in vitro study to be more effective than other treatments, Wild Child says. A recent study of 1,002 parents of children ages 6-13 found that 69% of parents said it was "extremely important" that lice treatment products not contain toxins, Wild Child notes...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.